BRPI0908052A2 - Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada - Google Patents

Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada

Info

Publication number
BRPI0908052A2
BRPI0908052A2 BRPI0908052-0A BRPI0908052A BRPI0908052A2 BR PI0908052 A2 BRPI0908052 A2 BR PI0908052A2 BR PI0908052 A BRPI0908052 A BR PI0908052A BR PI0908052 A2 BRPI0908052 A2 BR PI0908052A2
Authority
BR
Brazil
Prior art keywords
entacapone
levodopa
carbidopa
pharmaceutical compositions
enhanced bioavailability
Prior art date
Application number
BRPI0908052-0A
Other languages
English (en)
Inventor
Munish Talwar
Ritesh Kapoor
Manoj Mashalkar
Girish Kumar Jain
Original Assignee
Wockhardt Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Center filed Critical Wockhardt Research Center
Publication of BRPI0908052A2 publication Critical patent/BRPI0908052A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
BRPI0908052-0A 2008-02-06 2009-02-06 Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada BRPI0908052A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN263MU2008 2008-02-06
IN262MU2008 2008-02-06
PCT/IB2009/050486 WO2009098661A1 (en) 2008-02-06 2009-02-06 Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability

Publications (1)

Publication Number Publication Date
BRPI0908052A2 true BRPI0908052A2 (pt) 2015-08-11

Family

ID=40626854

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908052-0A BRPI0908052A2 (pt) 2008-02-06 2009-02-06 Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada

Country Status (16)

Country Link
US (2) US8709485B2 (pt)
EP (1) EP2252284B1 (pt)
JP (1) JP5466179B2 (pt)
KR (1) KR101444979B1 (pt)
CN (1) CN101939003A (pt)
AT (1) ATE510537T1 (pt)
AU (1) AU2009211028B2 (pt)
BR (1) BRPI0908052A2 (pt)
CA (1) CA2714112C (pt)
MX (1) MX2010008711A (pt)
NZ (1) NZ587168A (pt)
PL (1) PL2252284T3 (pt)
PT (1) PT2252284E (pt)
RU (1) RU2485947C2 (pt)
WO (1) WO2009098661A1 (pt)
ZA (1) ZA201005615B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229566A1 (en) * 2008-08-22 2011-09-22 Yatendra Kumar Gupta Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
KR101667762B1 (ko) * 2008-08-22 2016-10-20 욱크하르트 리미티드 엔타카폰 또는 이의 염의 서방형 약학 조성물
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
US9750702B2 (en) 2009-12-25 2017-09-05 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
BR112013027219A2 (pt) 2011-04-26 2016-12-27 Innopharmax Inc composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
WO2014151742A1 (en) * 2013-03-15 2014-09-25 Mylan, Inc. Formulation containing carbidopa, levodopa, and entacapone
ES2967693T3 (es) * 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
EP4356907A1 (en) 2014-09-04 2024-04-24 LobSor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
PT3209302T (pt) 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
CN106236720A (zh) * 2016-08-29 2016-12-21 海南通用康力制药有限公司 一种恩他卡朋的药物组合物及其制备方法
JP6934540B2 (ja) 2018-02-02 2021-09-15 東京エレクトロン株式会社 半導体装置の製造方法
AU2019237857A1 (en) 2018-03-23 2020-10-08 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
EP0437098A3 (en) * 1990-01-11 1991-09-18 Warner-Lambert Company Compressed confectionery tablets with at least two phases and sequential flavour delivery system
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
UA95954C2 (ru) 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа

Also Published As

Publication number Publication date
CA2714112C (en) 2015-08-11
ZA201005615B (en) 2011-10-26
US9089485B2 (en) 2015-07-28
EP2252284B1 (en) 2011-05-25
CA2714112A1 (en) 2009-08-13
PT2252284E (pt) 2011-08-23
JP5466179B2 (ja) 2014-04-09
AU2009211028A1 (en) 2009-08-13
KR101444979B1 (ko) 2014-10-07
AU2009211028B2 (en) 2013-12-05
US20110091558A1 (en) 2011-04-21
US8709485B2 (en) 2014-04-29
RU2010136935A (ru) 2012-03-20
ATE510537T1 (de) 2011-06-15
KR20100117097A (ko) 2010-11-02
RU2485947C2 (ru) 2013-06-27
PL2252284T3 (pl) 2011-10-31
US20140187644A1 (en) 2014-07-03
MX2010008711A (es) 2011-05-03
JP2011511061A (ja) 2011-04-07
EP2252284A1 (en) 2010-11-24
WO2009098661A1 (en) 2009-08-13
CN101939003A (zh) 2011-01-05
NZ587168A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
CR20110016A (es) Compuestos quimicos 251
CO6351689A2 (es) Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
ECSP10010295A (es) Formulacion de anticuerpo
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
ECSP066715A (pt)
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BRPI0916069A2 (pt) "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição"
MY159492A (en) Solid pharmaceutical formulation with delayed release
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]